# Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

> **NCT04668066** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 121 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** PF-07242813
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04668066
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-10
- **Primary completion:** 2022-12-27
- **Final completion:** 2022-12-27
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2024-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04668066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04668066, "Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04668066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*